nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo searchdiv qikanlogo popupnotification paper paperNew
2006, 05, 407-411
HBV病毒慢性感染疫苗治疗的组合策略及研究进展
基金项目(Foundation):
邮箱(Email):
DOI:
摘要:

关键词:
Abstract:

KeyWords:
参考文献

[1]Lok A S,McMahon B J.Chronic hepatitis B[J].Hepatology,2001,34:1225-1241.

[2]Chisari F V.Hepatitis B virus immunopathogenesis[J].Annu RevImmunol,1995,13:29-60.

[3]Guidotti L G,Rochford R,Chung J,et al.Viral clearance withoutdestruction of infected cells during acute HBV infection[J].Sci-ence,1999,254:825-829.

[4]Vandepapeliere P.Therapeutic vaccination against chronic viral infec-tions[J].Lancet,2002,2:353-367.

[5]Webster G J,Reignat S,Brown D,et al.Longitudinal analysis ofCD8+T cells specific for structural and nonstructural hepatitis Bvirus proteins in patients with chronic hepatitis B:implications forimmunotherapy[J].J Virol,2004,78:5709-5719.

[6]McClay H,Koch R,Chisari F V,et al.Relative sensitivity of hepatitisB virus and other hepatotropic viruses to the antiviral effects of cy-tokines[J].J Virol,2000,74:2255-2264.

[7]Wieland S F,Guidotti L G,Chisari F V.Intrahepatic induction ofalpha/beta interferon eliminates viral RNA-containing capsids inhepatitis B virus transgenic mice[J].J Virol,2000,74:4165-4173.

[8]Penna A,Del Prete G,Cavalli A,et al.Predominant T-helper cy-tokine profile of hepatitis B virus nucleocapsid-specific T cells in a-cute self-limited hepatitis B[J].Hepatology,1997,25:1022-1027.

[9]Jung M C,Hartmann B,Gerlach J T,et al.Virus-specific lymphokineproduction differs quantitatively but not qualitatively in acute andchronic hepatitis B infection[J].Virology,1998,261:165-172.

[10]Rehermann B,Lau D,Hoofnagle J H,et al.Cytotoxic T lymphocyteresponsiveness after resolution of chronic hepatitis B virus infection[J].J Clin Invest,1996,97:1655-1665.

[11]Boni C,Penna A,Ogg G S,et al.Lamivudine treatment can over-come cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy[J].Hepatology,2001,33:963-971.

[12]Boni C,Penna A,Bertoletti A,et al.Transient restoration of anti-vi-ral T cell responses induced by lamivudine therapy in chronic hep-atitis B[J].J Hepatol,2003,39:595-605.

[13]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].国际流行病学传染病学杂志,2006,33:2-11.

[14]Berzofsky J,Terabe M,Oh S K,et al.Progress on new vaccinestrategies for the immunotherapy and prevention of cancer[J].JClin Invest,2004,113:1515-1525.

[15]Michel M L,Mancini-Bourgine M.Therapeutic vaccination againstchronic hepatitis B virus infection[J].J Clin Virol,2005,34(Suppl1):108-114.

[16]Horiike N,Fazle Akbar S M,Michitaka K,et al.In vivoimmu-nization by vaccine therapy following virus suppression by lamivu-dine:a novel approach for treating patients with chronic hepatitis B[J].J Clin Virol,2005,32:156-161.

[17]Livingston B D,Alexander J,Crimi C,et al.Altered helper T lym-phocyte function associated with chronic hepatitis B virus infectionand its role in response to therapeutic vaccination in human[J].JImmunol,1999,162:3088-3095.

[18]Yang S H,Lee C G,Park S H,et al.Correlation of antiviral T-cellresponses with suppression of viral rebound in chronic hepatitis Bcarriers:a proof-of-concept study[J].Gene Therapy,2006,1-8.

[19]Chow Y H,Chiang B L,Lee Y L,et al.Development of Th1 andTh2 populations and the nature of immune responses to hepatitis Bvirus DNA vaccines can be modulated by codelivery of various cy-tokine genes[J].J Immunol,1998,160:1320-1329.

[20]Krieg A M.CpG motifs in bacterial DNA and their immune effects[J].Annu Rev Immunol,2002,20:709-760.

[21]Cooper C L,Davis H L,Morris M L,et al.CpG 7909,an immunos-timulatory TLR9 against oligodeoxynucleotide,an adjuvant toEgerix-B○R HBV vaccine in healthy adults:a double-blind phaseⅠ/Ⅱstudy[J].J Clin Immunol,2004,24:693-701.

[22]Trinchieri G.Interleukine-12 and the regulation of innate resistanceand adaptive immunity[J].Nat Rev Immunol,2003,3:133-146.

[23]Lohr H F,Pingel S,Bocher W O,et al.Reduced virus specific Thelper cell induction by autologous dentritic cells in patients withchronic hepatitis B:resporation by exogenous interleukin-12[J].Clin Exp Immunol,2002,130:107-114.

[24]Rigopoulou E,Suri D,Chorshi S,et al.Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B:antiviral and im-munological activity[J].Hepatology,2005,42:1028-1036.

[25]冯立,胡显文,陈惠鹏,等.治疗性乙型肝炎疫苗研究进展[J].生物技术通讯,2004,15:289-291.

[26]Wen Y M,Wu X H,Hu D C,et al.Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy[J].Lancet,1995,345:1575-1576.

[27]Xu D Z,Huang K L,Zhao K,et al.Vaccination with recombinationHBsAg-HBIG complex in healthy adults[J].Vaccine,2005,23(20):2658-2664.

[28]Wu T D,Wu Y Z,Jia I C,et al.Therapeutic polypeptides based onHBcAg 18-27 CTL epitope can induce antigen-secific CD8+CTL-mediated cytotoxicity in HLA-A2 transgenic mice[J].World J Gas-troenter,2004,10:1222-1226.

[29]Chen X,Li M,Le X,et al.Recombinant hepatitis B core antigencarrying PreS1 epitopes induce immune response against chronicHBV infection[J].Vaccine,2004,22:439-446.

[30]赵阳青,詹美云.乙型肝炎前S1抗原(1-42)与核心抗原(1-144)在大肠杆菌中表达的融合蛋白CS1的免疫原性研究[J].病毒学报,2001,17:333-337.

[31]许洪林,王四清,王世峰,等.两种CpG基序能高度活化人免疫细胞[J].中华微生物学与免疫学杂志,2001,21:471-475.

[32]田淑芳,宗芳,陈红,等.哺乳动物细胞分泌的乙型肝炎病毒表面S+PreS1融合抗原的理化和生物学性状[J].病毒学报,2002,18(4):312-316.

[33]孟昕,阮力,魏博,等.不同DNA疫苗联合接种可有效增强免疫效果[J].病毒学报,2000,16:212-218.

[34]陆柔剑,郭斐,娄元梅,等.表达乙型肝炎病毒表面抗原的非复制型重组痘苗病毒疫苗株RVJ123ΔCK的构建及其生物学性状鉴定[J].病毒学报,2003,19(1):27-30.

[35]Verrier B.Therapeutic vaccination from infectious disease:Lessonsfrom HIV-1[J].J Clin Virol,2005,34(suppl.1):S9-12.

[36]Maini M K,Boni C,Ogg G S,et al.Directex vivoanalysis of hep-atitis B virus-specific CD8(+)T cells associated with the control ofinfection[J].Gastroenterology,1999,117:1386-1396.

[37]Wherry E J,Teichgraber V,Becker T C,et al.Lineage relationshipand protective immunity of memory CD8+T cell subsets[J].NatImmunol,2003,4:225-234.

基本信息:

DOI:

中图分类号:R392

引用信息:

[1]谭文杰,阮力.HBV病毒慢性感染疫苗治疗的组合策略及研究进展[J].病毒学报,2006(05):407-411.

基金信息:

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文